A carregar...
Selexipag in the management of pulmonary arterial hypertension: an update
Selexipag is a compound that was designed to overcome the issues associated with oral administration of prostanoid compounds, beraprost and treprostinil in the treatment of pulmonary hypertension (PAH). As a selective IP agonist, it was designed to avoid the off-target prostanoid effects especially...
Na minha lista:
| Publicado no: | Drug Healthc Patient Saf |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6689562/ https://ncbi.nlm.nih.gov/pubmed/31496830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S181313 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|